Yasin Keshvargar
Lawyers
Filters
Revolution Medicines $2.2 billion common stock and convertible notes offerings
We advised the underwriters on the concurrent offerings
Ormat Technologies $1 billion convertible senior notes offering
We advised the representatives of the several initial purchasers on the offering
Novartis $11 billion notes offering
We advised Novartis on the investment-grade debt offering
Solid Biosciences $240 million private placement
We advised the lead placement agents
Korro Bio $85 million private placement
We advised the placement agents
MiniMed $560 million IPO
The carve-out IPO of Medtronic’s diabetes unit is the second largest medtech IPO ever
Revolution Medicines $1 billion at-the-market offering
We advised the sales agent on the offering
RXO $400 million senior notes offering
We advised the representative of the initial purchasers on the offering
Averin Capital Acquisition $250 million IPO
We advised the underwriters on the IPO
AgomAb Therapeutics $200 million IPO
We advised the representatives of the several underwriters on the IPO